CPCristina Pimenta

Cristina Pimenta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cristina Pimenta has a total of 272 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acceptability and Usability of Blood-Based and Oral Fluid HCV Self-Testing Among Men-Who-Have-Sex-with-Men and Transgender Women on PrEP

    by Hugo Perazzo, Sandra W. Cardoso, Thiago S. Torres, Daniel Bezerra, Ketiuce Zukeram, Marcos Benedetti, Julio Moreira, Brenda Hoagland, Cristina Pimenta, Beatriz Grinsztejn, et al.

    Hepatitis C virus self-testing (HCVST) has emerged as a potential strategy to expand testing among key populations. We assessed the feasibility of HCVST in cisgender men-who-have-sex-with-men (cis-MSM) and transgender women (TGW) on pre-exposure prophylaxis (PrEP). This cross-sectional study included cis-MSM or TGW attending a PrEP consultation in Rio de Janeiro (Brazil). Participants performed HCVST using blood-based and oral-fluid kits on the same day under observation. Difficulties, errors and assistance during HCVST were recorded. Re-reading and re-testing concordance [Kappa(k)] and values/preferences were assessed. A total of 250 participants (88% cis-MSM, age = 34 [IQR,28–41] years, 42% with high education level) were included. The main steps where participants requested assistance (95%CI) for blood-based HCVST were to add buffer [35.6%(29.9–41.8)] and to collect blood sample with the dropper [34.0%(28.4–40.1)]. The main error during oral fluid HCVST was incorrect collection of oral fluid [29.6% (95%CI,24.2–35.6)]. A total of 62.4% (95%CI,56.2–68.2) and 28.8% (95%CI,23.5–34.8) participants needed assistance in at least one step of blood-based and oral fluid HCVST, respectively. Lower education level was associated with higher odds of needing assistance for blood-based HCVST [aOR = 2.07 (95%CI,1.99–3.59), p = 0.009]. Re-reading and re-testing k-indexes were 0.92 and 0.89 for blood-based, and 1.00 and 0.75 for oral fluid HCVST, respectively. More than 95% of people felt safe; would repeat or would recommend HCVST. A total of 46.4% (95%CI,40.3–52.6) preferred oral fluid versus 36.4% (95%CI,30.6–42.6) who preferred blood-based. A relatively high proportion of participants needed assistance, especially for blood-based HCVST. Despite these challenges, high re-reading and re-testing agreements were observed and HCVST was well-accepted.

  • Open Access

    Person-centered choice and mHealth support for same-day delivery of long-acting injectable cabotegravir (ImPrEP CAB Brasil): a prospective, open-label, multicenter, quasi-experimental implementation study

    by Thiago Silva Torres, Brenda Hoagland, Carolina Coutinho, Mayara Secco Torres Silva, Ronaldo Ismério Moreira, Iuri Costa Leite, Marcelo Cunha, Emilia M. Jalil, Sandra Wagner Cardoso, Roberta Trefiglio, et al.


  • Open Access

    High syphilis incidence among PrEP‐adherent men who have sex with men and transgender women in Peru

    by Silver K. Vargas, Kelika A. Konda, Ronaldo I. Moreira, Iuri C. Leite, Marcelo Cunha, Brenda Hoagland, Juan V. Guanira, Marcos Benedetti, Cristina Pimenta, Beatriz Grinztejn, et al.

    Introduction: Syphilis remains a public health concern in Peru. Pre‐exposure prophylaxis (PrEP) implementation programmes in Latin America need to assess their impact on sexually transmitted infections (STIs), along with their feasibility. We assessed the relationship between PrEP adherence and syphilis incidence among men who have sex with men (MSM) and transgender women (TW) enrolled in ImPrEP, a multi‐country PrEP demonstration project; however, this analysis focuses on Peru.Methods: Between April 2018 and June 2021, 2292 HIV‐negative MSM/TW attending Peruvian STI clinics were enrolled and followed in ImPrEP. Participants had to be aged ≥18 years and report recent condomless anal sex (CAS), sex with a partner living with HIV, STI history (diagnosis/symptoms) and/or transactional sex. Quarterly follow‐up visits included PrEP dispensing, behavioural assessment, HIV and syphilis screening (treponemal test and Rapid Plasma Reagin [RPR] if syphilis negative at enrolment; RPR only if reactive‐treponemal test at baseline). PrEP adherence was assessed using the medication possession ratio (MPR: #pills prescribed / #days between visits). Generalized estimating equation (GEE) Poisson regression models were used to evaluate factors related to syphilis incidence and also assessed syphilis incidence during two periods: pre‐COVID‐19 lockdown (up to 16 March 2020) and during COVID‐19‐lockdown (17 March 2020−June 2021).Results: We enrolled 2039 cisgender‐MSM and 253 TW, with a median follow‐up time of 514 days; 205 incident syphilis cases were identified among 185 individuals. Overall syphilis incidence was 9.1 cases/100 person‐years (p.y.) (95% CI: 7.9−10.4), 14.7/100 p.y. (95% CI: 10.5−20.1) among TW and 8.3/100 p.y (95% CI: 7.1−10.0) among cisgender‐MSM. During the COVID‐19 pre‐lockdown period, syphilis incidence was 10.0/100 p.y. (95% CI: 8.3−12.1) and 8.1/100 p.y. (95% CI: 6.6−10.0) during‐lockdown. Multivariate GEE analysis showed higher syphilis incidence among PrEP‐adherent participants (MPR≥0.6) (adjusted incidence rate ratio [aIRR]: 1.46 [95% CI: 1.08−1.99]), those reporting receptive CAS (aIRR: 1.53 [95% CI: 1.11−2.11]) and TW (aIRR: 1.64 [95% CI: 1.08−2.51]). Syphilis incidence pre‐lockdown was higher for participants reporting receptive CAS (aIRR: 2.35 [95% CI: 1.43−3.86]); during‐lockdown, syphilis incidence was higher among those diagnosed with syphilis at enrolment (aIRR: 2.70 [95% CI: 1.67−4.36]).Conclusions: Syphilis incidence is high among PrEP‐adherent MSM/TW, those reporting receptive‐CAS and among TW. Health systems implementing PrEP should strengthen existing STI prevention strategies and incorporate new ones, like Doxy‐PEP for PrEP‐adherent MSM, TW and individuals engaging in receptive‐CAS. MPR may be a tool to identify PrEP users at risk for syphilis.


  • Open Access

    Exploring perceptions and preferences for PrEP choice and of an mHealth intervention: insights from the ImPrEP CAB‐Brasil study

    by Cristina Pimenta, Claudio G. Mann, Brenda Hoagland, Eduardo Carvalheira, Cristina Jalil, Marcos Benedetti, Nilo Fernandes, Carolina Coutinho, Emilia M. Jalil, Mayara Secco Torres Silva, et al.

    Introduction: Although the efficacy of long‐acting injectable cabotegravir (CAB‐LA) for pre‐exposure prophylaxis (PrEP) is well‐known from clinical trials, research is needed to guide effective strategies for its implementation. We describe a qualitative study to assess perceptions and preferences for PrEP choice and acceptability of an mHealth intervention within the ImPrEP CAB Brasil study.Methods: ImPrEP CAB Brasil is an implementation study of same‐day delivery of CAB‐LA for young sexual and gender minorities (SGM; 18–30 years) in oral PrEP public health clinics in six Brazilian cities. At enrolment, participants received counselling on HIV prevention (SOC) or SOC+mHealth tool to choose between oral or injectable PrEP. The mHealth tool consisted of five videos describing HIV combined prevention including PrEP options. A subset of participants from each site were invited to participate in the qualitative study (October 2023−July 2024). Semi‐structured interviews were conducted, recorded and transcribed. Data were fed into ATLAS.ti.24 software. Conventional content analysis was used for coding categories based on an inductive reasoning process.Results: We conducted 120 interviews (48 SOC and 72 SOC+mHealth; 107 CAB‐LA and 13 oral PrEP). Participants reported not knowing about CAB‐LA before enrolment; some recently heard from a partner or friend. Reasons for choosing CAB‐LA were perceived convenience, practicality, easier adherence to bimonthly injections and higher efficacy compared to oral PrEP. Reasons for not choosing CAB‐LA were fear of injections and pain. Reasons for choosing oral PrEP included perspective of less appointments, easiness of daily adherence, access in case of travel and the option to stop immediately if desired or needed. Reasons for not choosing oral PrEP included forgetfulness of daily intake, gastrointestinal side effects, fear of inadvertent exposure and judgement by family. Participants found the mHealth educational tool useful and adequate for PrEP education and decision‐making.Conclusions: Perceptions for PrEP choice among SGM underscore the importance of providing comprehensive information and support towards decision‐making processes, so users can have an accurate understanding of each PrEP option, as well as their clinical and social benefits. The mHealth tool was perceived as highly desirable and useful for PrEP education, having the potential to be implemented in HIV prevention services.Clinical Trial Number: NCT05515770


  • Open Access

    A Comprehensive Molecular and Serological Investigation of Hepatitis A Virus Among Patients With Suspected Acute Hepatitis: A Brazilian Study

    by Ketty Gleyzer de Oliveira, Mariana Pinheiro Alves Vasconcelos, Julia Teixeira Ton, Silvia Naomi de Oliveira Uehara, Roberta Sitnik, Denize Ornelas Pereira Salvador de Oliveira, Layze Castberg, Ricardo Andreotti Siqueira, Peter James Robinson, Thaís Senna de Paula Domingues, et al.

    Hepatitis A Virus (HAV) infects millions of individuals annually and is a major cause of acute viral hepatitis worldwide. This study aims to (1) assess HAV infection in suspected acute hepatitis patients at public healthcare institutions in Brazil; (2) evaluate the proportion of immunized individuals against HAV; (3) identify HAV genotypes; (4) examine the association between HAV infection and demographic data, as well as exposure to risk factors. This is a prospective, observational multicenter study conducted in primary health services in Brazil from October 2019 to May 2023, involving 1721 patients with suspected acute hepatitis. Acute HAV infection was identified in 108 (6.3%) patients, predominantly in young men (80%) and from South and Southeast regions of Brazil (97%). Anti‐HAV IgG, indicating previous exposure or vaccination, was detected in 78.6% of individuals (74% in the South to 91% in the North). Genotype I.A was found in all cases and approximately 450 mutations were identified, most of them in the structural proteins VP1‐3. Two viral groups were identified and related to two introductions of the virus: cosmopolitan sequences from North America, South America, and Europe, and a minor group of Brazilian sequences similar to Asian and South American ones. The high incidence of acute HAV infections highlights the need for targeted prevention and vaccination strategies. The characterization of HAV genetic diversity and molecular epidemiology contributes to monitoring and identifying emerging outbreaks.


  • Open Access

    Profiles of Willingness to Use Pre-Exposure Prophylaxis Modalities and an HIV prevention vaccine among Brazilian, Mexican and Peruvian Sexual and Gender Minorities: A Cross-Sectional Online Survey (Preprint)

    by Jazmin Qquellon, Kelika A. Konda, Oliver Elorreaga, Hamid Vega-Ramirez, Centli Guillén-Díaz-Barriga, Dulce Díaz-Sosa, Brenda Hoagland, Juan V. Guanira, Marcos Benedetti, Cristina Pimenta, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Despite recent advances, pre-exposure prophylaxis (PrEP) scale-up remains slow in Latin America. Understanding PrEP modality preferences can help design effective implementation. Objective: The aim of this study was to describe willingness to use different PrEP modalities among sexual and gender minorities (SGM) aged 18+ years from Brazil, Mexico and Peru, and factors associated with willingness to use four PrEP modalities. Methods: We conducted a cross-sectional online survey in 2021. We used multivariate Poisson regression to estimate prevalence ratios, identifying differences in willingness to use daily oral, event-driven oral, monthly oral and bimonthly injectable PrEP. Models for each PrEP modality were adjusted for age, country, race, education, income, HIV risk score, HIV testing, and HIV risk perception. Results: Among 27,589 individuals who initiated the survey, 16,951 were included (Brazil: 61.3%; Mexico: 29.5%; Peru: 9.3%). Mean age was 32 years, and 67.8% had more than secondary education. Most respondents were willing to use monthly oral (74.4%), daily oral (65.8%), and bimonthly injectable (60.2%), while only 38.0% were willing to use event-driven oral PrEP. Across modalities, willingness was higher among those with increased HIV risk perception and high HIV sexual exposure. Willingness was lower among Peruvian respondents for all modalities, except event-driven PrEP. Participants with lower education had lower willingness to use monthly oral and bimonthly injectable PrEP. Conclusions: Our results suggest a preference for long-acting formulations among SGM in Latin America. Further research is needed to address gaps in the understanding of prevention modalities and to guide potential users in selecting the most suitable PrEP modality available.


  • Open Access

    Preparing for the Implementation of Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis Within the Brazilian Public Health System (ImPrEP CAB Brasil): Qualitative Study

    by M Cristina Pimenta, Thiago Silva Torres, Brenda Hoagland, Mirian Cohen, Claudio Gruber Mann, Cristina M Jalil, Eduardo Carvalheira, Lucilene Freitas, Nilo Fernandes, Debora Castanheira, et al.

    Background: Although long-acting, injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) has proven efficacious for HIV prevention in clinical trials, research is needed to guide effective implementation in real-world settings. Formative work with community members and health care providers (HCPs) is important to provide insight into the needs and contexts of specific populations and reveal potential barriers and facilitators for implementation projects. Objective: We aimed to describe the results from formative work to develop an implementation package for CAB-LA PrEP within the ImPrEP CAB Brasil study. Methods: ImPrEP CAB Brasil is an implementation study of same-day delivery of CAB-LA PrEP for young sexual and gender minority (SGM) groups (aged 18-30 years) in 6 existing oral PrEP public health clinics. We conducted formative research to prepare for the implementation of ImPrEP CAB Brasil through community mobilization, process mapping with HCPs with experience in CAB-LA, and focus group discussions (FGDs) with young SGM groups (n=92) and HCPs (n=20) to identify initial perceptions of facilitators and barriers for CAB-LA PrEP implementation, refine the mobile health (mHealth) educational tool, and evaluate the acceptability of using a text message appointment reminder intervention through WhatsApp. FGDs were recorded, transcribed, systematically coded, and analyzed with thematic categorization by trained researchers using a qualitative data analysis program ATLAS.ti (version 7). Results: A community mobilization team comprising 34 SGM community leaders collaborated in creating a prototype for an mHealth educational tool and contributed to the planning of peer education activities. We created 3 process maps for each site to describe the initial visit, follow-up visits, and laboratory flow. The main challenge identified for same-day CAB-LA PrEP delivery was the extended duration of clinic visits due to the numerous laboratory tests and HIV counseling steps required. Proposed solutions included having point-of-care HIV rapid tests instead of laboratory tests and additional counseling staff. Barriers for CAB-LA PrEP implementation identified through FGDs were the training of HCPs, support for adherence to injection appointments, and stigma or discrimination against SGM groups and persons using PrEP. The mHealth educational tool and WhatsApp reminders were highly acceptable by SGM groups and HCPs, indicating their potential to support PrEP choice and adherence. Content analysis on the cultural appropriateness of the language and overall clarity of the material contributed to the refinement of the mHealth tool. Conclusions: Structured formative work with SGM persons and HCPs generated important refinements to context-specific materials and plans to launch ImPrEP CAB Brasil in public health clinics. Ongoing implementation monitoring will use the process maps to identify additional barriers and potential solutions to same-day delivery of CAB-LA PrEP. Summative evaluations are needed to measure the effectiveness of the mHealth educational tool to support PrEP choice and the use of WhatsApp appointment reminders.


  • Open Access

    Preparing for the Implementation of Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis Within the Brazilian Public Health System (ImPrEP CAB Brasil): Qualitative Study (Preprint)

    by M Cristina Pimenta, Thiago Silva Torres, Brenda Hoagland, Mirian Cohen, Claudio Gruber Mann, Cristina M Jalil, Eduardo Carvalheira, Lucilene Freitas, Nilo Fernandes, Debora Castanheira, et al.

    BACKGROUND Although long-acting, injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) has proven efficacious for HIV prevention in clinical trials, research is needed to guide effective implementation in real-world settings. Formative work with community members and health care providers (HCPs) is important to provide insight into the needs and contexts of specific populations and reveal potential barriers and facilitators for implementation projects. OBJECTIVE We aimed to describe the results from formative work to develop an implementation package for CAB-LA PrEP within the ImPrEP CAB Brasil study. METHODS ImPrEP CAB Brasil is an implementation study of same-day delivery of CAB-LA PrEP for young sexual and gender minority (SGM) groups (aged 18-30 years) in 6 existing oral PrEP public health clinics. We conducted formative research to prepare for the implementation of ImPrEP CAB Brasil through community mobilization, process mapping with HCPs with experience in CAB-LA, and focus group discussions (FGDs) with young SGM groups (n=92) and HCPs (n=20) to identify initial perceptions of facilitators and barriers for CAB-LA PrEP implementation, refine the mobile health (mHealth) educational tool, and evaluate the acceptability of using a text message appointment reminder intervention through WhatsApp. FGDs were recorded, transcribed, systematically coded, and analyzed with thematic categorization by trained researchers using a qualitative data analysis program ATLAS.ti (version 7). RESULTS A community mobilization team comprising 34 SGM community leaders collaborated in creating a prototype for an mHealth educational tool and contributed to the planning of peer education activities. We created 3 process maps for each site to describe the initial visit, follow-up visits, and laboratory flow. The main challenge identified for same-day CAB-LA PrEP delivery was the extended duration of clinic visits due to the numerous laboratory tests and HIV counseling steps required. Proposed solutions included having point-of-care HIV rapid tests instead of laboratory tests and additional counseling staff. Barriers for CAB-LA PrEP implementation identified through FGDs were the training of HCPs, support for adherence to injection appointments, and stigma or discrimination against SGM groups and persons using PrEP. The mHealth educational tool and WhatsApp reminders were highly acceptable by SGM groups and HCPs, indicating their potential to support PrEP choice and adherence. Content analysis on the cultural appropriateness of the language and overall clarity of the material contributed to the refinement of the mHealth tool. CONCLUSIONS Structured formative work with SGM persons and HCPs generated important refinements to context-specific materials and plans to launch ImPrEP CAB Brasil in public health clinics. Ongoing implementation monitoring will use the process maps to identify additional barriers and potential solutions to same-day delivery of CAB-LA PrEP. Summative evaluations are needed to measure the effectiveness of the mHealth educational tool to support PrEP choice and the use of WhatsApp appointment reminders.

  • Open Access

    Recent HIV infection and annualized HIV incidence rates among sexual and gender minorities in Brazil and Peru (ImPrEP seroincidence study): a cross-sectional, multicenter study

    by Thiago S. Torres, Sylvia L.M. Teixeira, Brenda Hoagland, Kelika A. Konda, Monica Derrico, Ronaldo I. Moreira, Juan V. Guanira, Marcos Benedetti, Sandro Nazer, Gino M. Calvo, et al.


  • Open Access

    Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study

    by Beatriz Grinsztejn, Thiago Silva Torres, Brenda Hoagland, Emilia Moreira Jalil, Ronaldo Ismerio Moreira, Gabrielle O'MAlley, Starley B Shade, Marcos R Benedetti, Julio Moreira, Keila Simpson, et al.

    Background: Long-acting injectable cabotegravir (CAB-LA) for preexposure prophylaxis (PrEP) has proven efficacious in randomized controlled trials. Further research is critical to evaluate its effectiveness in real-world settings and identify effective implementation approaches, especially among young sexual and gender minorities (SGMs). Objective: ImPrEP CAB Brasil is an implementation study aiming to generate critical evidence on the feasibility, acceptability, and effectiveness of incorporating CAB-LA into the existing public health oral PrEP services in 6 Brazilian cities. It will also evaluate a mobile health (mHealth) education and decision support tool, digital injection appointment reminders, and the facilitators of and barriers to integrating CAB-LA into the existing services. Methods: This type-2 hybrid implementation-effectiveness study includes formative work, qualitative assessments, and clinical steps 1 to 4. For formative work, we will use participatory design methods to develop an initial CAB-LA implementation package and process mapping at each site to facilitate optimal client flow. SGMs aged 18 to 30 years arriving at a study clinic interested in PrEP (naive) will be invited for step 1. Individuals who tested HIV negative will receive mHealth intervention and standard of care (SOC) counseling or SOC for PrEP choice (oral or CAB-LA). Participants interested in CAB-LA will be invited for step 2, and those with undetectable HIV viral load will receive same-day CAB-LA injection and will be randomized to receive digital appointment reminders or SOC. Clinical appointments and CAB-LA injection are scheduled after 1 month and every 2 months thereafter (25-month follow-up). Participants will be invited to a 1-year follow-up to step 3 if they decide to change to oral PrEP or discontinue CAB-LA and to step 4 if diagnosed with HIV during the study. Outcomes of interest include PrEP acceptability, choice, effectiveness, implementation, and feasibility. HIV incidence in the CAB-LA cohort (n=1200) will be compared with that in a similar oral PrEP cohort from the public health system. The effectiveness of the mHealth and digital interventions will be assessed using interrupted time series analysis and logistic mixed models, respectively. Results: During the third and fourth quarters of 2022, we obtained regulatory approvals; programmed data entry and management systems; trained sites; and performed community consultancy and formative work. Study enrollment is programmed for the second quarter of 2023. Conclusions: ImPrEP CAB Brasil is the first study to evaluate CAB-LA PrEP implementation in Latin America, one of the regions where PrEP scale-up is most needed. This study will be fundamental to designing programmatic strategies for implementing and scaling up feasible, equitable, cost-effective, sustainable, and comprehensive alternatives for PrEP programs. It will also contribute to maximizing the impact of a public health approach to reducing HIV incidence among SGMs in Brazil and other countries in the Global South. Trial Registration: Clinicaltrials.gov NCT05515770; https://clinicaltrials.gov/ct2/show/NCT05515770 International Registered Report Identifier (IRRID): PRR1-10.2196/44961